← Return to Home Page

WG Critical Care, LLC/HQ Specialty Pharma Corporation announces acquisition of QUARTERMASTER®

WG Critical Care, LLC, a fully integrated pharmaceutical company, announced today that it and its affiliate, HQ Specialty Pharma Corporation, signed an agreement with West Agro, Inc. to acquire the rights for QUARTERMASTER® Suspension (penicillin-dihydrostreptomycin in oil), FDA approved, for intramammary use to reduce the frequency of existing infection and to prevent new infections with Staphylococcus aureus in dry cows.

"Mastitis in cows has a significant impact on the global dairy industry, adversely affecting both the quality and quantity of dairy products, ultimately resulting in lower consumer confidence and reduced profits for dairy farmers," said Vincent M. Durante, Senior Vice President, WG Critical Care. "For almost forty years, QUARTERMASTER Suspension has been trusted by veterinarians and producers to help prevent the likelihood of intramammary infections during the critical dry-off period in the bovine lactation cycle. WG Critical Care is committed to ensuring that this highly valued product continues to be available for the treatment and prevention of mastitis in dairy cows."

Durante continued, "As discussed in a study that assessed intramammary infections postcalving, cure of preexisting infections over the dry period, prevention of new infections during the dry period, and risk for a clinical mastitis case between calving and 100 days in milk, there was no difference in efficacy between QUARTERMASTER Suspension and a third-generation cephalosporin in affecting a bacteriological cure. In the context of promoting prudent use of antimicrobials, the authors discussed the potential value of making first-generation antimicrobials like QUARTERMASTER Suspension the first choice for prophylactic treatment of dry cows.1"

Fernando Cuccioli, President of West Agro, added, "We are pleased to be able to keep the QUARTERMASTER product in the marketplace and excited about WG Critical Care's plans to build on the already strong brand."

QUARTERMASTER Suspension is a combination of one million units of Procaine Penicillin G, and 1 g of Dihydrostreptomycin base, as Dihydrostreptomycin Sulfate. QUARTERMASTER Suspension is supplied in pails containing 144 x 10 mL syringes and 144 convenient single-use alcohol pads. QUARTERMASTER Suspension is also supplied in cartons containing 12 x 10 mL syringes with 12 convenient single-use alcohol pads.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Under the terms of the agreement, WG Critical Care became the exclusive licensee of the QUARTERMASTER brand, and HQ Specialty Pharma Corporation acquired the rights to the NADA 055-028. Manufacturing will take place in the original production facility located in Hamilton, NY. The transaction closed October 18th and product availability is expected during first quarter 2014.

Reference:

  1. Arruda A, Godden S, Rapnicki P et al. Randomized noninferiority clinical trial  evaluating 3 commercial dry cow mastitis preparations: I. Quarter-level outcomes. J Dairy Sci. 96(7):4419-4435;2013.

 

background_banner